{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:20Z","timestamp":1790217380686,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.ajo.2009.05.031","type":"journal-article","created":{"date-parts":[[2009,8,6]],"date-time":"2009-08-06T04:51:36Z","timestamp":1249534296000},"page":"536-543.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["A Systematic Analysis of the Off-Label Use of Bevacizumab for Severe Retinopathy of Prematurity"],"prefix":"10.1016","volume":"148","author":[{"given":"Jonathan A.","family":"Micieli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Surkont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2009.05.031_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0140-6736(97)01107-0","article-title":"Retinopathy of prematurity in middle-income countries","volume":"350","author":"Gilbert","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2009.05.031_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1091-8531(99)70091-1","article-title":"Childhood blindness","volume":"3","author":"Steinkuller","year":"1999","journal-title":"J AAPOS"},{"key":"10.1016\/j.ajo.2009.05.031_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ajo.2009.05.031_bib4","first-page":"1201","article-title":"The effect of oxygen on vasoformative cell division","volume":"36","author":"Chan-Ling","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2009.05.031_bib5","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.ajo.2009.05.031_bib6","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"Smith","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2009.05.031_bib7","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajo.2009.05.031_bib8","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1073\/pnas.93.10.4851","article-title":"Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy","volume":"93","author":"Robinson","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajo.2009.05.031_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-008-0952-y","article-title":"A systematic review on the effect of bevacizumab in exudative age-related macular degeneration","volume":"247","author":"Schouten","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/157339909787314121","article-title":"Intravitreal bevacizumab for diabetic retinopathy","volume":"5","author":"Arevalo","year":"2009","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.ajo.2009.05.031_bib11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1136\/bjo.84.12.1383","article-title":"Diode laser treatment of posterior retinopathy of prematurity","volume":"84","author":"Axer-Siegel","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","article-title":"Outcome of zone 1 retinopathy of prematurity","volume":"81","author":"O'Keefe","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ajo.2009.05.031_bib13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3928\/0191-3913-20030701-06","article-title":"Laser treatment of zone I prethreshold and stage 3 threshold retinopathy of prematurity","volume":"40","author":"Recsan","year":"2003","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.ajo.2009.05.031_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1067\/mpa.2000.107904","article-title":"Zone I retinopathy of prematurity","volume":"4","author":"Katz","year":"2000","journal-title":"J AAPOS"},{"key":"10.1016\/j.ajo.2009.05.031_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/archopht.1990.01070040047029","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity","volume":"108","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib16","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ajo.2009.05.031_bib18","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib20","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","article-title":"Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study","volume":"126","author":"Kong","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","article-title":"Intravitreal bevacizumab (Avastin) for post-laser anterior segment ischemia in aggressive posterior retinopathy of prematurity","volume":"55","author":"Shah","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib22","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2009.05.031_bib23","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2009.05.031_bib25","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2009.05.031_bib26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.1996.01100140419009","article-title":"Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity","volume":"114","author":"Pierce","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib27","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.ajo.2009.05.031_bib28","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2009.05.031_bib29","doi-asserted-by":"crossref","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","article-title":"Endogenous VEGF is required for visual function: evidence for a survival role on M\u00fcller cells and photoreceptors","volume":"3","author":"Saint-Geniez","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ajo.2009.05.031_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0002-9440(10)65138-3","article-title":"Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris","volume":"155","author":"Blaauwgeers","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajo.2009.05.031_bib31","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1101\/gad.322904","article-title":"Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve","volume":"18","author":"Schwarz","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.ajo.2009.05.031_bib32","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1523\/JNEUROSCI.19-14-05731.1999","article-title":"Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival, and Schwann cell proliferation in the peripheral nervous system","volume":"19","author":"Sondell","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/j.ajo.2009.05.031_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","article-title":"Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury","volume":"171","author":"Nishijima","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajo.2009.05.031_bib34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2009.05.031_bib35","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1159\/000083889","article-title":"Differential effects of transforming growth factor-beta on the synthesis of connective tissue growth factor and vascular endothelial growth factor by peritoneal mesothelial cell","volume":"99","author":"Szeto","year":"2005","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.ajo.2009.05.031_bib36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.preteyeres.2008.05.002","article-title":"The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration","volume":"27","author":"Grisanti","year":"2008","journal-title":"Prog Retina Eye Res"},{"key":"10.1016\/j.ajo.2009.05.031_bib37","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1582-4934.2005.tb00499.x","article-title":"Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy","volume":"9","author":"Malik","year":"2005","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ajo.2009.05.031_bib38","first-page":"290","article-title":"Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity","volume":"37","author":"Stone","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2009.05.031_bib39","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","article-title":"Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity","volume":"115","author":"Sonmez","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.05.031_bib40","doi-asserted-by":"crossref","first-page":"23463","DOI":"10.1074\/jbc.274.33.23463","article-title":"Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1","volume":"274","author":"Antonetti","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajo.2009.05.031_bib41","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1167\/iovs.06-0322","article-title":"VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability","volume":"47","author":"Harhaj","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2009.05.031_bib42","first-page":"H2735","article-title":"VEGF induces NO-dependent hyperpermeability in coronary venules","volume":"271","author":"Wu","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ajo.2009.05.031_bib43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1161\/CIRCRESAHA.108.178467","article-title":"An ezrin\/calpain\/PI3K\/AMPK\/eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production","volume":"104","author":"Youn","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.ajo.2009.05.031_bib44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ophtha.2008.09.046","article-title":"Cerebrovascular accidents in ranibizumab","volume":"116","author":"Ueta","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.05.031_bib45","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2009.05.031_bib46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/bjo.2007.128371","article-title":"VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity","volume":"92","author":"Pieh","year":"2008","journal-title":"Br J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939409003869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939409003869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:00:09Z","timestamp":1757595609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939409003869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0002939409003869"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2009.05.031","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Analysis of the Off-Label Use of Bevacizumab for Severe Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2009.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}